Primer: Prescient Therapeutics (PTX AU) - Aug 2026
Prescient Therapeutics is a clinical-stage oncology company with a dual-focus pipeline: targeted small-molecule drugs (PTX-100 and PTX-200) and...
103 Views
Prescient Therapeutics - PTX-100 to target RhoA-mutant lymphomas
Prescient Therapeutics is planning a clinical trial of PTX-100 in RhoA-mutant lymphomas, a niche indication where the company could potentially...
221 Views
Update on Astellas (4503) As It Gets Orphan Drug Status for Gilteritinib
News that gilteritinib has received orphan drug status for acute myeloid leukaemia (AML) would be rather more exciting for Astellas (4503 JP) but...
347 Views
No more insights